🏛️ Verified NIH Record • Updated 2024-11-24
INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4) (NCT02730338)
INTense ExeRcise for SurviVAL Among Men with Metastatic Prostate Cancer (INTERVAL - GAP4): a Multicentre, Randomised, Controlled, Phase III Study
🔵 Active, Not Recruiting Observational / Diagnostic 🧠 Behavioral & Psychological Program Sponsor: Movember Foundation
🩺 Plain-English Summary (8th-Grade Level)
To determine if supervised high intensity aerobic and resistance training increases overall survival compared to self-directed exercise in patients with metastatic prostate cancer.
Who can join: Review the eligibility criteria below.
Location: Cedars Sinai Medical Centre — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
- High intensity aerobic and resistance training (BEHAVIORAL)
- Psychosocial support (BEHAVIORAL)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (18 Sites)
- Cedars Sinai Medical Centre — Los Angeles, California
- UCSF — San Francisco, California
- UC Denver — Denver, Colorado
- University of Minnesota — Minneapolis, Minnesota
- Oregon Health & Science University — Portland, Oregon
- Fred Hutchinson Cancer Centre — Seattle, Washington
- Australian Prostate Cncr Research Centre — Brisbane, Queensland
- University of Queensland — Brisbane, Queensland
- Victoria University / Sunshine Hospital — Melbourne, Victoria
- Edith Cowan University — Perth, Western Australia
- University of Alberta — Edmonton, Alberta
- Centre Hospitalier de l'Université de Montréal (CRCHUM) — Montreal,
- German Sport University Cologne — Cologne,
- Erasmus MC — Rotterdam,
- University of Surrey — Guildford, Surrey
- Queen's University Belfast — Belfast,
- University of Glasgow — Glasgow,
- Kings College London — London,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Prostate Cancer
- Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC — Boston, Massachusetts
- PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer — Boston, Massachusetts
- Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer — Detroit, Michigan
- Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer — Basking Ridge, New Jersey
- Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers — New York, New York
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC — Tucson, Arizona
Explore by condition: All Metastatic Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.